Most plasma collected at donation centers is sent to large-scale manufacturing facilities where it’s broken down into specific proteins used to treat serious and often life-threatening medical conditions. A smaller portion goes directly to hospitals for emergency transfusions. The United States supplies roughly 71% of the world’s source plasma, making American donors the backbone of a global treatment pipeline that millions of patients depend on.
Paid Centers vs. Blood Banks: Two Different Paths
Where your plasma ends up depends largely on where you donated it. Plasma collected at commercial, paid-donation centers (like BioLife, CSL Plasma, or Grifols) is classified as “source plasma.” It’s frozen and shipped to pharmaceutical manufacturing plants, where it becomes the raw material for injectable protein therapies. This is the vast majority of plasma collected in the U.S.
Plasma collected at nonprofit blood banks or during hospital blood drives follows a different route. That plasma is typically separated from whole blood donations and stored as fresh frozen plasma, which hospitals use directly for patient transfusions. Some of this plasma, if it isn’t needed locally, gets shipped to fractionation facilities and enters the same manufacturing pipeline as commercially collected plasma.
How Plasma Gets Turned Into Medicine
Raw plasma is a complex soup of hundreds of proteins. Manufacturing facilities use a process called fractionation to isolate the ones with medical value. The core technique has been refined over decades but still relies on a method called cold ethanol precipitation: technicians adjust the temperature, acidity, and alcohol concentration of the plasma in a series of precise steps, causing different proteins to clump together and fall out of solution at each stage. Those clumps are separated by spinning them in a centrifuge or filtering them out, and each fraction is then purified further using advanced chromatography techniques.
The end result is a set of highly purified protein concentrates, each one packaged as a distinct pharmaceutical product. Three categories account for the bulk of what’s produced: immunoglobulins (antibodies), albumin, and clotting factors.
Immunoglobulin Therapies: The Biggest Use
The single largest product made from donated plasma is immunoglobulin, a concentrated preparation of antibodies. These therapies serve two broad purposes: replacing missing immune function and calming an overactive immune system.
People born with primary immunodeficiency disorders don’t produce enough antibodies on their own. Without regular immunoglobulin infusions, they’re vulnerable to repeated, severe infections. Treating just one of these patients requires more than 130 plasma donations per year, which gives a sense of the enormous volume of plasma the supply chain needs. Immunoglobulin replacement is also used for patients whose immune systems have been weakened by cancer treatments or other medical interventions.
The same product, given at higher doses, acts as an immune modulator for autoimmune and neurological conditions. It’s a standard treatment for Guillain-Barré syndrome, a condition where the immune system attacks the nerves and can cause rapid-onset paralysis. It’s also used for Kawasaki disease in children, various forms of inflammatory muscle disease, scleroderma, and other conditions where the body’s defenses turn against its own tissues. In inflammatory muscle disease, about 85% of patients treated with immunoglobulin therapy meet criteria for a clinically meaningful response.
Albumin: Keeping Fluids Where They Belong
Albumin is the most abundant protein in blood plasma, and its main job is maintaining fluid balance. It keeps liquid inside blood vessels instead of leaking into surrounding tissues. When patients lose that ability, the consequences are serious and fast.
Purified albumin from donated plasma is used in hospitals for patients with severe liver disease who need large-volume fluid drainage from the abdomen. It’s given alongside antibiotics for a dangerous infection of abdominal fluid called spontaneous bacterial peritonitis. Burn patients with injuries covering more than 30% of their body receive albumin infusions after the first 24 hours to stabilize their circulation. In all of these cases, the patient’s own albumin levels have dropped so low that their body can’t maintain blood pressure or organ function without outside help.
Clotting Factors: Treating Bleeding Disorders
People with hemophilia and other inherited bleeding disorders lack specific proteins their blood needs to form clots. Before plasma-derived clotting factor concentrates became available, even minor injuries or routine dental work could be life-threatening for these patients. Plasma fractionation produces purified concentrates of the missing factors, which patients infuse on a regular schedule to prevent spontaneous bleeding episodes or use on demand when injuries occur.
Another plasma-derived product targets a genetic condition called alpha-1 antitrypsin deficiency. People with this disorder don’t produce enough of a protein that protects the lungs from damage. Without treatment, they develop early-onset emphysema. The therapy involves regular intravenous infusions of purified alpha-1 antitrypsin concentrate, typically dosed every two weeks to maintain a protective level in the bloodstream. The protein has a half-life of about nine days, which is why patients need ongoing infusions rather than a one-time treatment.
Fresh Frozen Plasma in Trauma Care
Not all plasma goes through fractionation. Fresh frozen plasma, kept intact with all its proteins, is a critical resource in hospital trauma centers. When a patient arrives with severe injuries and massive blood loss, their blood loses its ability to clot properly. This condition, called trauma-induced coagulopathy, is one of the leading causes of preventable death in trauma patients.
Current trauma protocols call for giving fresh frozen plasma alongside red blood cell transfusions at roughly a 1-to-1 ratio. A landmark clinical trial called PROPPR established this approach, and a more recent study of nearly 2,000 patients with severe blunt trauma found that a high plasma-to-red-cell ratio was independently associated with better survival. Some evidence suggests that ratios as high as 1 to 1.5 may be beneficial for the most severely injured patients.
Laboratory Research and Diagnostics
A portion of collected plasma, particularly units that don’t meet the strict standards for human injection, finds its way into research laboratories and diagnostic manufacturing. Plasma is used as a substrate for viral detection studies, biomarker research, and large-scale analyses of proteins and metabolites. Its technical advantages over serum (faster processing, higher yield per unit of blood, no complications from clotting) make it a preferred material for many types of lab work. Diagnostic companies also use plasma to calibrate and validate the test kits hospitals rely on for routine blood work.
The Scale of Global Demand
The demand for plasma-derived therapies has grown steadily for decades, driven by better diagnosis of immune disorders, expanded uses for immunoglobulin, and aging populations worldwide. With U.S. donors providing about 71% of the global source plasma supply, American donation centers are effectively the pharmacy for patients around the world. Plasma collected in Texas or Ohio may be fractionated in a facility in Europe and shipped as finished medicine to a hospital in Asia.
This concentration of supply in one country creates a fragile system. Disruptions at U.S. collection centers, like the drop in donations seen during the early months of the COVID-19 pandemic, ripple outward to patients globally. Each donation feeds into a manufacturing process that takes seven to twelve months from collection to finished product, so shortages aren’t felt immediately but can take years to fully resolve once they develop.